218 related articles for article (PubMed ID: 29559521)
1. FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver.
Papazyan R; Liu X; Liu J; Dong B; Plummer EM; Lewis RD; Roth JD; Young MA
J Lipid Res; 2018 Jun; 59(6):982-993. PubMed ID: 29559521
[TBL] [Abstract][Full Text] [Related]
2. Farnesoid X Receptor Activation by Obeticholic Acid Elevates Liver Low-Density Lipoprotein Receptor Expression by mRNA Stabilization and Reduces Plasma Low-Density Lipoprotein Cholesterol in Mice.
Singh AB; Dong B; Kraemer FB; Xu Y; Zhang Y; Liu J
Arterioscler Thromb Vasc Biol; 2018 Oct; 38(10):2448-2459. PubMed ID: 30354208
[TBL] [Abstract][Full Text] [Related]
3. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.
Pencek R; Marmon T; Roth JD; Liberman A; Hooshmand-Rad R; Young MA
Diabetes Obes Metab; 2016 Sep; 18(9):936-40. PubMed ID: 27109453
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
[TBL] [Abstract][Full Text] [Related]
5. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
[TBL] [Abstract][Full Text] [Related]
6. Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR.
Dong B; Singh AB; Guo GL; Young M; Liu J
Int J Mol Med; 2019 May; 43(5):1927-1938. PubMed ID: 30896855
[TBL] [Abstract][Full Text] [Related]
7. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
8. FXR activation promotes intestinal cholesterol excretion and attenuates hyperlipidemia in SR-B1-deficient mice fed a high-fat and high-cholesterol diet.
Singh AB; Dong B; Kraemer FB; Liu J
Physiol Rep; 2020 Mar; 8(5):e14387. PubMed ID: 32170842
[TBL] [Abstract][Full Text] [Related]
9. A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor.
Narayanan AK; Surendran S; Balakrishnan D; Gopalakrishnan U; Malick S; Valsan A; Philips CA; Watson CJE
Curr Rev Clin Exp Pharmacol; 2024; 19(3):225-233. PubMed ID: 38708917
[TBL] [Abstract][Full Text] [Related]
10. Regulation of Intestinal UDP-Glucuronosyltransferase 1A1 by the Farnesoid X Receptor Agonist Obeticholic Acid Is Controlled by Constitutive Androstane Receptor through Intestinal Maturation.
Weber AA; Mennillo E; Yang X; van der Schoor LWE; Jonker JW; Chen S; Tukey RH
Drug Metab Dispos; 2021 Jan; 49(1):12-19. PubMed ID: 33154041
[TBL] [Abstract][Full Text] [Related]
11. 3β-Isoobeticholic acid efficiently activates the farnesoid X receptor (FXR) due to its epimerization to 3α-epimer by hepatic metabolism.
Stefela A; Kaspar M; Drastik M; Holas O; Hroch M; Smutny T; Skoda J; Hutníková M; Pandey AV; Micuda S; Kudova E; Pavek P
J Steroid Biochem Mol Biol; 2020 Sep; 202():105702. PubMed ID: 32505574
[TBL] [Abstract][Full Text] [Related]
12. Regulation of lipid metabolism by obeticholic acid in hyperlipidemic hamsters.
Dong B; Young M; Liu X; Singh AB; Liu J
J Lipid Res; 2017 Feb; 58(2):350-363. PubMed ID: 27940481
[TBL] [Abstract][Full Text] [Related]
13. Obeticholic acid protects mice against lipopolysaccharide-induced liver injury and inflammation.
Xiong X; Ren Y; Cui Y; Li R; Wang C; Zhang Y
Biomed Pharmacother; 2017 Dec; 96():1292-1298. PubMed ID: 29174575
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic Acid Ameliorates Valproic Acid-Induced Hepatic Steatosis and Oxidative Stress.
Gai Z; Krajnc E; Samodelov SL; Visentin M; Kullak-Ublick GA
Mol Pharmacol; 2020 May; 97(5):314-323. PubMed ID: 32098797
[TBL] [Abstract][Full Text] [Related]
15. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
[TBL] [Abstract][Full Text] [Related]
16. Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
Hambruch E; Miyazaki-Anzai S; Hahn U; Matysik S; Boettcher A; Perović-Ottstadt S; Schlüter T; Kinzel O; Krol HD; Deuschle U; Burnet M; Levi M; Schmitz G; Miyazaki M; Kremoser C
J Pharmacol Exp Ther; 2012 Dec; 343(3):556-67. PubMed ID: 22918042
[TBL] [Abstract][Full Text] [Related]
17. Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
Ghosh Laskar M; Eriksson M; Rudling M; Angelin B
J Intern Med; 2017 Jun; 281(6):575-585. PubMed ID: 28145001
[TBL] [Abstract][Full Text] [Related]
18. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
19. Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.
Adorini L; Rigbolt K; Feigh M; Roth J; Erickson M
PLoS One; 2024; 19(4):e0300809. PubMed ID: 38662778
[TBL] [Abstract][Full Text] [Related]
20. Opposite effects of the FXR agonist obeticholic acid on Mafg and Nrf2 mediate the development of acute liver injury in rodent models of cholestasis.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Bordoni M; Roselli R; Di Giorgio C; Baldoni M; Ricci P; Monti MC; Morretta E; Zampella A; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Sep; 1865(9):158733. PubMed ID: 32371093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
